(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

USRE50497E1 · kind E1 · reissue

Assignee

• GlaxoSmithKline LLC · US

Inventors

• Brandon Heath Brown · Burlingame, US
• Ernest A. Carra · Foster City, US
• Jeffrey N. Hemenway · San Mateo, US
• Henry Morrison · Dublin, US
• Troy Reynolds · San Francisco, US
• Bing Shi · Redwood City, US
• Dimitrios Stefanidis · Mountain View, US
• Fang Wang · Foster City, US
• Matthew Robert Warr · Madison, US
• James Andrew Whitney · Guilford, US
• Yan Xin · Redwood City, US

Key dates

• Filing date: Jan 25, 2023
• Grant date: Jul 22, 2025
• Expiry date: Jan 25, 2043

Classification

• Technology area (CPC —): General

Abstract

The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.